Brown & Brown Q1 2026: Revenue Surge from Accession, but Organic Growth Flat

What happened

Brown & Brown reported Q1 2026 total revenues of $1.9B, up 35.4% year-over-year, driven primarily by the Accession acquisition. However, organic revenue was flat, and organic revenue including contingents grew only 2.2%, signaling a sharp deceleration from the mid-single-digit growth seen in 2025. Diluted net income per share was $1.06, while adjusted diluted EPS came in at $1.39, reflecting margin expansion from the larger scale. The company also declared a quarterly dividend of $0.165 per share, consistent with its capital return policy. The flat organic growth is a key watch item from the DeepValue report, which had assumed sustained mid-single-digit organic expansion, and raises questions about underlying demand and integration traction.

Implication

The flat organic revenue (ex-contingents) is a negative surprise relative to the mid-single-digit growth expected, and the 35.4% total revenue increase is entirely acquisition-driven, masking underlying weakness. While adjusted EPS of $1.39 suggests margin improvement, the organic stagnation raises concerns about core momentum and the pace of Accession integration. If this flatness persists into Q2 and Q3, it could trigger a downgrade of the thesis from BUY to HOLD. However, integration is still early, and synergies may take time to materialize, so it is not yet a sell signal. The dividend increase to $0.165 per quarter is positive but expected, and does not offset the growth deceleration. Investors should focus on organic growth trends and producer retention metrics in the coming quarters to gauge the health of the franchise.

Thesis delta

The DeepValue report assumed sustained mid-single-digit organic growth as a key pillar for the BUY stance. Q1 2026's flat organic revenue (2.2% with contingents) represents a material deceleration from the 2025 run rate, challenging that assumption. If this weakness is not transient and reflects integration friction or market share loss, the thesis would shift from BUY to HOLD until organic momentum recovers.